Volume 23, Number 1—January 2017
CME ACTIVITY - Research
Analysis of Anthrax Immune Globulin Intravenous with Antimicrobial Treatment in Injection Drug Users, Scotland, 2009–2010
Table 3
Initial physical findings of recipients and nonrecipients of AIG-IV, Scotland, UK, 2009–2010*
Physical finding | AIG-IV nonrecipient | AIG-IV recipient | p value |
---|---|---|---|
Vital signs [reference value]† | |||
Temperature, °C, mean ± SE [36.1–37.2°C] | 37.3 ± 0.3, n = 28 | 36.3 ± 0.4, n = 15 | 0.05 |
Systolic BP, mmHg, mean ± SE [90–140 mm Hg] | 113.6 ± 3.8, n = 28 | 117.2 ± 5.0, n = 15 | 0.57 |
Diastolic BP, mmHg, mean ± SE [60–90 mm Hg] | 65.9 ± 3.0, n = 28 | 68.6 ± 4.3, n = 15 | 0.59 |
Mean BP, mmHg, median (IQR) [70–100 mm Hg] | 83.5 (74.3–90.7), n = 28 | 88.0 (67.7–93.3), n = 15 | 0.57 |
Heart rate, beats/min, mean ± SE [60–100 beats/min] | 104.0 ± 4.7, n = 28 | 102.4 ± 5.3, n = 15 | 0.83 |
Respiratory rate, breaths/min, mean ± SE [12–20 breaths/min] | 18.8 ± 1.4, n = 28 | 19.9 ± 1.7, n = 13 | 0.64 |
Glasgow coma score, median (IQR) [15] |
15 (15–15), n = 28 |
15 (15–15), n = 15 |
0.56 |
Skin and limbs | |||
Skin lesion | 85.2 (23/27) | 73.3 (11/15) | 0.43 |
Ulcer | 35.3 (6/17) | 10 (1/10) | 0.20 |
Exude | 27.8 (5/18) | 18.2 (2/11) | 0.68 |
Limb mottling | 26.7 (4/15) | 60 (6/10) | 0.12 |
Eschar | 17.7 (3/17) | 18.2 (2/11) | 1.00 |
Local pain | 100 (19/19) | 85.7 (12/14) | 0.17 |
Localized edema | 95.8 (23/24) | 93.3 (14/15) | 1.00 |
Local erythema | 87.0 (20/23) | 92.3 (12/13) | 1.00 |
Limb pain | 89.5 (17/19) | 46.7 (7/15) | 0.01 |
Limb edema |
84 (21/25) |
46.7 (7/15) |
0.03 |
Findings other than skin and limb | |||
Fever | 60.9 (14/23) | 66.7 (8/12) | 1.00 |
Diaphoresis | 63.6 (7/11) | 40 (4/10) | 0.39 |
Lethargy | 64.3 (9/14) | 41.7 (5/12) | 0.25 |
Nausea | 29.4 (5/17) | 30 (3/10) | 1.00 |
Abdomen pain | 6.7 (1/15) | 20 (2/10) | 0.54 |
Confusion | 35.3 (6/17) | 0 (0/13) | 0.02 |
*Values are % patients (no. patients with the finding/no. patients for whom data were available) except as indicated. n values indicate no. patients for whom data were available. Bold indicates statistical difference between AIG-IV recipients and nonrecipients. AIG-IV, anthrax immune globulin intravenous; BP. blood pressure; IQR, interquartile range.
1These authors contributed equally to this article.